LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, […]readmore
Tags : Oxford BioMedica
Shots: OXB to receive $4.83M as an option exercise fee & ~$37.96M in development, regulatory & sales milestones along with royalty on sales of a CF gene therapy product under […]readmore
Shots: The companies have signed an 18mos. supply agreement under a 3yrs. master supply and development agreement. Oxford Biomedica to receive $17.95M up front as a capacity reservation fee and […]readmore
Shots: Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s […]readmore
Shots: Oxford Biomedica and VMIC entered into a five-year agreement for the manufacturing of adenovirus vector-based COVID-19 vaccine, AZD1222 for scaling up the production of the vaccine from the summer […]readmore
Shots: Oxford Biomedica has joined the consortium, which is led by the Jenner Institute, University of Oxford and also includes the VMIC, Pall Life Sciences, Cobra Biologics, and Halix BV […]readmore
Shots: Oxford Biomedica to receive $10M up front in cash, ~$86M as development and regulatory milestones, ~ $131M as commercial milestones and royalties on sales of products developed by Juno […]readmore
Shots: The ongoing AXO-Lenti-PD (also known OXB-102) study evaluates efficacy, safety, tolerability and measuring motor function in patients with PD. The closure of initial results from study is expected in […]readmore